AmideBio Awarded SBIR Phase IIB Grant to Support Pre-Clinical Development of its Long-Acting Stable Glucagon Analog for the Treatment of Hyperinsulinism

BOULDER, Colo., Oct. 4, 2022 /PRNewswire/ — AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $2.69M in funding through a Phase IIB Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.